Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
NEW YORK and CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that long-term follow up data from a completed Phase 1/2 study evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) will be presented at the 77th Annual Meeting of the Society for Investigative Dermatology (SID), being held May 8-11 in Chicago. The data will be presented by Stanford University researcher Shaundra Eichstadt, M.D. in two forums at the meeting, as detailed below.
As previously reported, these data showed that three years after treatment with EB-101, a majority of RDEB patients had durable wound healing. Notable improvements were also reported in outcomes associated with wound healing, including patient reported reductions in pain and itching. No serious treatment-related adverse events were observed at three years, and no replication competent virus was present at any time point.
Genetically corrected autologous keratinocyte epidermal grafts improve wound healing and patient reported outcomes in patients with recessive dystrophic epidermolysis bullosa (RDEB)
Selected e-Poster Discussion I
Thursday, May 9, 11:15 a.m. – 12:15 p.m. CT
Poster Session III
Saturday, May 11, 12:45 – 2:45 p.m. CT
EB-101 is an investigational, autologous, gene-corrected cell therapy poised to enter late-stage development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder without an approved therapy. Treatment with EB-101 involves using gene transfer to deliver COL7A1 genes into a patient’s own skin cells (keratinocytes) and transplanting them back to the patient to enable normal Type VII collagen expression and skin function. In the U.S., Abeona holds Regenerative Medicine Advanced Therapy, Breakthrough Therapy, and Rare Pediatric designations for EB-101 and Orphan Drug designation in both the U.S. and EU.
About Recessive Dystrophic Epidermolysis Bullosa
Recessive dystrophic epidermolysis bullosa, or RDEB, is a rare connective tissue disorder without an approved therapy in which patients suffer with severe epidermal wounds that bring pain, itching, and widespread complications impacting the length and quality of their lives. People with RDEB have a defect in the COL7A1 gene, leaving them unable to produce Type VII collagen that helps anchor the dermal and epidermal layers of the skin.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. The Company’s clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, as well as ABO-102 and ABO-101, novel AAV9-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB). The Company’s portfolio of AAV9-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Its preclinical assets include ABO-401, which uses the novel AIM™ AAV vector platform to address all mutations of cystic fibrosis. Abeona has received numerous regulatory designations from the FDA and EMA for its pipeline candidates and is the only company with Regenerative Medicine Advanced Therapy designation for two investigational therapies (EB-101 and ABO-102). For more information, visit www.abeonatherapeutics.com.
Forward Looking Statement
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements include statements regarding our pipeline including the potential use of investigational product EB-101 in the treatment of recessive dystrophic epidermolysis bullosa (RDEB) based upon pre-clinical data. We have attempted to identify forward looking statements by such terminology as “may,” will,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” and similar expressions.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to: continued interest in our rare disease portfolio, our ability to initiate and enroll patients in clinical trials, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other risks as may be detailed from time to time in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or update them to reflect events or circumstances occurring after the date of this presentation, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Senior Director, Investor Relations
+1 (646) 813-4710
Director, Corporate Communications
+1 (718) 344-5843
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
BOURBON: Press release - Update on the search operations of the Bourbon Rhode crew12.10.2019 09:00:00 CEST | Press release
Marseilles, October 12, 2019 Update on the search operations of the Bourbon Rhode crew Following the report of a possible distress flare on the night of Sunday 6 to Monday October 7, the CROSS French West Indies-Guyana (Regional Operational Centre for Surveillance and Rescue) dispatched 4 ships to search the area, with the support of an overflight by the US Coast Guards aircraft. Over the past week, search has been intense and extensive to try to detect a sign after on the one hand, the report of this potential distress flare and on the other hand, the satellite photo obtained from the European Maritime Safety Agency (EMSA). These new searches have unfortunately been unsuccessful. As a whole, search operations have not found any trace of life or life rafts for more than 10 days now despite measures of exceptional magnitude. As a reminder, search and rescue operations have been going on for 16 days, with the sinking of the ship taking place on September 26 as it faced hurricane Lorenzo.
Agfa-Gevaert: Publication of a transparency notification (AOC) – Regulated information11.10.2019 17:40:00 CEST | Press release
(Article 14 of the law of May 2, 2007 on the disclosure of significant shareholdings) Mortsel, Belgium – October 11, 2019 – 5.40 p.m. CET According to Agfa-Gevaert NV’s bylaws, the threshold as from which a shareholding needs to be disclosed, has been set at 3%, 5% and a multiple of 5%. In conformity with the Law of May 2, 2007 regarding the disclosure of significant shareholdings in listed companies, Agfa-Gevaert (Euronext: AGFB) discloses the following declaration: Active Ownership Capital S.à.r.l. has announced on April 18, 2019, that it managed a stake in Agfa-Gevaert as per April 12, 2019 of 23,069,853 voting rights or 13.42% (denominator is 171,851,042). On this date, AOC Value S.A.S. individually held 13,402,784 voting rights or 7.80%. On April 12, 2019, Active Ownership Fund SICAV-FIS SCS contributed 4,535,000 shares already held by it in Agfa-Gevaert NV to AOC Technology S.A.S., as a result of which AOC Technology S.A.S. directly holds 9,667,069 voting rights or 5.63% of Agfa-
DNO ASA: Mandatory Notification of Trade11.10.2019 16:56:00 CEST | Press release
Oslo, 11 October 2019 - DNO ASA, the Norwegian oil and gas operator, has today purchased 1,900,000 own shares at an average price of NOK 13.0887 per share. Following this transaction, DNO holds 73,200,000 own shares. -- For further information, please contact: Media: email@example.com Investors: firstname.lastname@example.org -- DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands, Ireland and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
PRF: Unaudited preliminary consolidated turnover of AS PRFoods in the 3rd quarter of 201911.10.2019 16:28:00 CEST | Press release
PRFoods’ unaudited preliminary consolidated turnover in 3Q 2019 (i.e. 1Q of the fiscal year 2019/2020) amounted to EUR 19.32 million euros (19.40 million euros in 3Q 2018). The third quarter of 2019 was characterized by a general decline of raw material prices for fish products, resulting in lower prices for both fish and fish fillets, and smoked products. Despite the ca 5% decrease in the price of the Group’s main products, we managed to increase the share of other fish products and keep the total turnover largely at the level of last year. The turnover of other fish products increased by 1.01 million euros, whereas turnover from smoked fish product group and raw fish and fillets’ product group decreased by 0.54 million euros and 0.48 million euros, respectively. The Group’s revenue structure has changed both in regard to product groups as well as client groups compared to the same period a year ago. The share of other fish products increased by 5.30 percentage points. The share of ra
Conditions for Inflation-linked auctions11.10.2019 16:20:00 CEST | Press release
Sveriges Riksbank Bid procedure details Inflation-linked Government Bonds, 2019-10-18 Maturity date Loan ISIN code Coupon Volume, SEK million 2026-06-01 3112 SE0008014062 0.125 % 250 +/- 250 2028-12-01 3104 SE0000556599 3.50 % 250 +/- 250 Settlement date 2019-10-22 Bids have to be entered by 10.00 on OCT 18, 2019 Highest permitted bid volume: 250 SEK million Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON OCT 18, 2019. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se
Conditions for Riksbank Bid Procedures Sek Bonds11.10.2019 16:20:00 CEST | Press release
Sveriges Riksbank Bid procedure details Government Bonds, 2019-10-17 Maturity date Loan ISIN code Coupon Volume, SEK million 2023-11-13 1057 SE0004869071 1.50 % 500 +/- 250 2029-11-12 1061 SE0011281922 0.75 % 500 +/- 250 Settlement date 2019-10-21 Bids have to be entered by 10.00 on OCT 17, 2019 Highest permitted bid volume: 500 SEK million in issue SGB 1057 and 500 SEK million in issue SGB 1061 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON OCT 17, 2019. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se